BRPI1006438A2 - terapia adjuvante de cancer - Google Patents

terapia adjuvante de cancer

Info

Publication number
BRPI1006438A2
BRPI1006438A2 BRPI1006438A BRPI1006438A BRPI1006438A2 BR PI1006438 A2 BRPI1006438 A2 BR PI1006438A2 BR PI1006438 A BRPI1006438 A BR PI1006438A BR PI1006438 A BRPI1006438 A BR PI1006438A BR PI1006438 A2 BRPI1006438 A2 BR PI1006438A2
Authority
BR
Brazil
Prior art keywords
cancer therapy
adjuvant cancer
adjuvant
therapy
cancer
Prior art date
Application number
BRPI1006438A
Other languages
English (en)
Inventor
Eric Hedrick
Gwendolyn Fyfe
Norman Wolmark
Robert D Mass
Original Assignee
Genentech Inc
Nsabp Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc, Nsabp Foundation Inc filed Critical Genentech Inc
Publication of BRPI1006438A2 publication Critical patent/BRPI1006438A2/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Fertilizers (AREA)
BRPI1006438A 2009-04-20 2010-04-20 terapia adjuvante de cancer BRPI1006438A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US17100809P 2009-04-20 2009-04-20
US17131809P 2009-04-21 2009-04-21
US18119509P 2009-05-26 2009-05-26
PCT/US2010/031740 WO2010123891A1 (en) 2009-04-20 2010-04-20 Adjuvant cancer therapy

Publications (1)

Publication Number Publication Date
BRPI1006438A2 true BRPI1006438A2 (pt) 2016-09-27

Family

ID=42235124

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1006438A BRPI1006438A2 (pt) 2009-04-20 2010-04-20 terapia adjuvante de cancer

Country Status (19)

Country Link
US (1) US20100266589A1 (pt)
EP (1) EP2421558A1 (pt)
JP (1) JP2012524083A (pt)
KR (1) KR20120096401A (pt)
CN (1) CN102458467A (pt)
AR (1) AR076344A1 (pt)
AU (1) AU2010239368A1 (pt)
BR (1) BRPI1006438A2 (pt)
CA (1) CA2759030A1 (pt)
CL (1) CL2011002610A1 (pt)
CO (1) CO6450651A2 (pt)
CR (1) CR20110553A (pt)
IL (1) IL215764A0 (pt)
MA (1) MA33323B1 (pt)
MX (1) MX2011010955A (pt)
RU (1) RU2011147051A (pt)
SG (1) SG175289A1 (pt)
TW (1) TW201106969A (pt)
WO (1) WO2010123891A1 (pt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2664738C (en) * 2006-09-29 2017-03-07 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
ES2575152T3 (es) 2009-10-16 2016-06-24 Oncomed Pharmaceuticals, Inc. Combinación terapéutica y uso de anticuerpos antagonistas de DLL4 y agentes antihipertensores
WO2011078301A1 (ja) 2009-12-25 2011-06-30 ファーマロジカルズ・リサーチ プライベート リミテッド Nog樹立癌細胞株が移植された非ヒト動物モデルを用いた抗癌剤ターゲット探索及びスクリーニング法
CA2800913C (en) 2010-06-03 2019-07-23 Pharmacyclics, Inc. The use of inhibitors of bruton's tyrosine kinase (btk)
US8551479B2 (en) 2010-09-10 2013-10-08 Oncomed Pharmaceuticals, Inc. Methods for treating melanoma
SG189302A1 (en) 2010-10-06 2013-05-31 Pharmalogicals Res Pte Ltd Cancer stem cell population and method for production thereof
EP2749641B1 (en) 2011-09-07 2021-06-02 Chugai Seiyaku Kabushiki Kaisha Cancer stem cell isolation
MX361712B (es) 2011-09-23 2018-12-14 Oncomed Pharm Inc Agentes de ligacion al factor de crecimiento endotelial vascular/ligando 4 similar a delta (vegf/dell4) y usos de los mismos.
EP2772268B8 (en) 2011-10-28 2020-01-08 Chugai Seiyaku Kabushiki Kaisha Cancer stem cell-specific molecule
SG11201407859YA (en) * 2012-05-31 2014-12-30 Genentech Inc Methods of treating cancer using pd-l1 axis binding antagonists and vegf antagonists
BR112015001690A2 (pt) 2012-07-24 2017-11-07 Pharmacyclics Inc mutações associadas com a resistência a inibidores da tirosina quinase de bruton (btk)
SG11201500903XA (en) * 2012-08-07 2015-03-30 Genentech Inc Combination therapy for the treatment of glioblastoma
JP6371294B2 (ja) 2012-10-31 2018-08-08 オンコメッド ファーマシューティカルズ インコーポレイテッド Dll4アンタゴニストによる処置の方法およびモニタリング
BR112015010059A2 (pt) 2012-11-02 2017-07-11 Pharmacyclics Inc terapia adjuvante com inibidor da quinase da família tec
US20140348821A1 (en) * 2013-05-24 2014-11-27 Nsabp Foundation, Inc. Defective Mismatch Repair and Benefit from Bevacizumab for Colon Cancer
US10456470B2 (en) 2013-08-30 2019-10-29 Genentech, Inc. Diagnostic methods and compositions for treatment of glioblastoma
US10617755B2 (en) 2013-08-30 2020-04-14 Genentech, Inc. Combination therapy for the treatment of glioblastoma
US9885086B2 (en) 2014-03-20 2018-02-06 Pharmacyclics Llc Phospholipase C gamma 2 and resistance associated mutations
WO2016011052A1 (en) 2014-07-14 2016-01-21 Genentech, Inc. Diagnostic methods and compositions for treatment of glioblastoma
PT3212233T (pt) 2014-10-31 2020-07-16 Oncomed Pharm Inc Terapia combinada para o tratamento de doenças
WO2017042318A1 (en) * 2015-09-10 2017-03-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Chemerin polypeptide for the treatment of cancer-induced cachexia
CA2999160A1 (en) 2015-09-23 2017-03-30 Oncomed Pharmaceuticals, Inc. Methods and compositions for treatment of cancer

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6582959B2 (en) * 1991-03-29 2003-06-24 Genentech, Inc. Antibodies to vascular endothelial cell growth factor
US20030206899A1 (en) * 1991-03-29 2003-11-06 Genentech, Inc. Vascular endothelial cell growth factor antagonists
WO1994004679A1 (en) * 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5730977A (en) * 1995-08-21 1998-03-24 Mitsui Toatsu Chemicals, Inc. Anti-VEGF human monoclonal antibody
US20020032315A1 (en) * 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
US6884879B1 (en) * 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
TR199903123T2 (xx) * 1997-04-07 2000-05-22 Genentech, Inc. Anti-Vegf antikorlar�.
US6703020B1 (en) * 1999-04-28 2004-03-09 Board Of Regents, The University Of Texas System Antibody conjugate methods for selectively inhibiting VEGF
RU2005136988A (ru) * 2003-05-30 2006-06-10 Дженентек, Инк. (Us) Лечение антителами против vegf
US20050106667A1 (en) * 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
US7758859B2 (en) * 2003-08-01 2010-07-20 Genentech, Inc. Anti-VEGF antibodies
US20060009360A1 (en) * 2004-06-25 2006-01-12 Robert Pifer New adjuvant composition
BRPI0720552A2 (pt) * 2006-12-19 2014-01-07 Genentech Inc Antagonistas específicos de vegf para terapia adjuvante e neoadjuvante e o tratamento de tumores em estágio precoce
BRPI0806414A2 (pt) * 2007-02-01 2011-09-06 Genentech Inc método para tratamento de tumor
TWI468417B (zh) * 2007-11-30 2015-01-11 Genentech Inc 抗-vegf抗體

Also Published As

Publication number Publication date
RU2011147051A (ru) 2013-05-27
KR20120096401A (ko) 2012-08-30
CA2759030A1 (en) 2010-10-28
JP2012524083A (ja) 2012-10-11
US20100266589A1 (en) 2010-10-21
TW201106969A (en) 2011-03-01
IL215764A0 (en) 2012-01-31
MA33323B1 (fr) 2012-06-01
CR20110553A (es) 2012-01-23
CL2011002610A1 (es) 2012-04-09
CO6450651A2 (es) 2012-05-31
MX2011010955A (es) 2012-04-02
SG175289A1 (en) 2011-11-28
CN102458467A (zh) 2012-05-16
EP2421558A1 (en) 2012-02-29
WO2010123891A1 (en) 2010-10-28
AR076344A1 (es) 2011-06-01
AU2010239368A1 (en) 2011-11-10

Similar Documents

Publication Publication Date Title
BRPI1006438A2 (pt) terapia adjuvante de cancer
BR112012005594A2 (pt) tratamento de câncer
HK1175476A1 (en) Cancer treatment
DE602009000539D1 (de) Strahlentherapiegerät
BR112012002797A2 (pt) tratamento de câncer de próstata
ATE526024T1 (de) Fluvoxamin vermeidende pirfenidontheraphy
GB0916666D0 (en) Photodynamic therapy device
BRPI1013618A2 (pt) pirimidinas substituídas para o tratamento de câncer
BR112013011659A2 (pt) métodos de tratamento do câncer
BRPI1010874A2 (pt) composição para o tratamento de câncer de próstata
BRPI1007995A2 (pt) orto-aminoamidas para o tratamento de cãncer.
BRPI0922884A2 (pt) compostos para tratamento de câncer
IL222958A0 (en) Cancer treatment
EP2346531A4 (en) TUMOR VACCINE
GB201003293D0 (en) Cancer vaccine
GB2471750B (en) Radiation therapy device
BRPI0918508A2 (pt) orto-aminoanilidas para o tratamento de câncer
BRPI1013903A2 (pt) tratamentos terapêuticos utilizando centaquina
EP2585115A4 (en) ANTICANCER TREATMENT
GB0910751D0 (en) Prostate cancer vaccine
EP2473613A4 (en) KREBSAUSHUNGERUNGSTHERAPIE
GB0916997D0 (en) Combination therapy
GB0902916D0 (en) Antibody therapy
GB0809046D0 (en) Cancer treatment
GB0907973D0 (en) Combination therapy

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]